MEETING ABSTRACT



Open Access

OR13-002 Recessive mutations in CECR1, encoding adenosine deaminase 2 (ADA2), cause systemic and cutaneous polyarteritis nodosa (PAN)

E Levy-Lahad^{1*}, P Elkan-Navon¹⁺, R Segel¹⁺, SB Pierce²⁺, T Walsh², J Barash³, S Padeh⁴, A Zlotogorski⁵, YY Berkun⁵, JJ Press⁶, M Mukamel⁶, PJ Hashkes¹, LL Harel⁶, M Tekin^{7,8}, F Yalcinkaya⁷, O Kasapcopur⁹, EF Emirogullari⁸, MK Lee², RE Klevit², PF Renbaum¹, A Weinberg-Shukron¹, S Zeligson¹, D Marek-Yagel⁴, M Shohat¹⁰, A Singer¹¹, E Pras⁴, AA Rubinow⁵, Y Anikster⁴, M-C King²

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switerland. 22-26 May 2013

Introduction

Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of middle-sized arteries, found in both adults and children. Disease pathogenesis is poorly understood. We identified multiple cases of systemic PAN and cutaneous PAN in families and individuals of Georgian-Jewish ancestry, consistent with autosomal recessive inheritance. While most cases (17/20) had childhood onset, cutaneous PAN could also initiate in middle age.

Objectives

To determine the genetic basis of monogenic PAN.

Methods

Exome sequencing of 4 affected individuals from 2 families was followed by targeted sequencing of 16 additional Georgian-Jewish cases and 6 Turkish pediatric cases of PAN. Mutations were assayed by protein structure analysis, expression in mammalian cells, biophysical analysis of purified protein, and enzymatic activity in patient sera.

Results

Missense mutation CECR1 p.G47R (c.139G>A), in the gene encoding ADA2, was the only damaging variant homozygous in all 4 exomes. Of the 20 Georgian-Jewish patients, 19 were homozygous for this mutation and one was compound heterozygous for G47R and H391Y. One

Turkish patient was compound heterozygous for G47V and W264S. In the Georgian-Jewish population, the frequency of G47R was 0.05, reflecting the high prevalence of PAN in this endogamous community. The other mutations were absent from ethnically matched controls.

ADA2 activity was significantly reduced in patient sera. Expression of mutant proteins in HEK293T cells yielded significantly reduced levels of secreted ADA2 and biophysical assays indicated reduced protein stability.

Conclusion

We report mutations in the gene encoding ADA2 as the first genetic cause of a systemic vasculitis. ADA2 is the major extra-cellular ADA, so blood vessels may be particularly vulnerable to loss of its catalytic and immune growth factor activity.

Disclosure of interest

None declared.

Authors' details

¹Shaare Zedek Medical Center, Jerusalem, Israel. ²University of Washington, Seattle, USA. ³Kaplan Medical Center, Rehovoth, Israel. ⁴Sheba Medical Center, Tel Hashomer, Israel. ⁵Hadassah Medical Center, Jerusalem, Israel. ⁶Schneider Children's Medical Center, Petach Tikvah, Israel. ⁷Ankara University, Ankara, Turkey. ⁸University of Miami, Miami, USA. ⁹Istanbul University, Istanbul, Turkey. ¹⁰Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel. ¹¹Barzilai Medical Center, Ashkelon, Israel.

† Contributed equally

¹Shaare Zedek Medical Center, Jerusalem, Israel

Full list of author information is available at the end of the article



© 2013 Levy-Lahad et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published: 8 November 2013

doi:10.1186/1546-0096-11-S1-A264

Cite this article as: Levy-Lahad *et al.*: **OR13-002** Recessive mutations in CECR1, encoding adenosine deaminase 2 (ADA2), cause systemic and cutaneous polyarteritis nodosa (PAN). *Pediatric Rheumatology* 2013 11(Suppl 1):A264.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

BioMed Central